Gainor et al[34] retrospectively studied 58 NSCLC patients treated with ICI (monotherapy or in combination with EGFR-TKI or chemotherapy): 22 patients with EGFR mutations, 6 with ALK translocations, and 30 without molecular alterations. This evidence concerns the gene EGFR and non-small cell lung carcinoma.